Literature DB >> 25934076

Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer.

Armin Wiegering1,2, Friedrich W Uthe1, Thomas Jamieson3, Yvonne Ruoss1, Melanie Hüttenrauch1, Maritta Küspert4, Christina Pfann1, Colin Nixon3, Steffi Herold1, Susanne Walz1,5, Lyudmyla Taranets5, Christoph-Thomas Germer2,5, Andreas Rosenwald5,6, Owen J Sansom3, Martin Eilers1,5.   

Abstract

UNLABELLED: Deregulated expression of MYC is a driver of colorectal carcinogenesis, suggesting that inhibiting MYC may have significant therapeutic value. The PI3K and mTOR pathways control MYC turnover and translation, respectively, providing a rationale to target both pathways to inhibit MYC. Surprisingly, inhibition of PI3K does not promote MYC turnover in colon carcinoma cells, but enhances MYC expression because it promotes FOXO-dependent expression of growth factor receptors and MAPK-dependent transcription of MYC. Inhibition of mTOR fails to inhibit translation of MYC, because levels of 4EBPs are insufficient to fully sequester eIF4E and because an internal ribosomal entry site element in the 5'-untranslated region of the MYC mRNA permits translation independent of eIF4E. A small-molecule inhibitor of the translation factor eIF4A, silvestrol, bypasses the signaling feedbacks, reduces MYC translation, and inhibits tumor growth in a mouse model of colorectal tumorigenesis. We propose that targeting translation initiation is a promising strategy to limit MYC expression in colorectal tumors. SIGNIFICANCE: Inhibiting MYC function is likely to have a significant therapeutic impact in colorectal cancers. Here, we explore several strategies to target translation initiation in order to block MYC expression. We show that a small-molecule inhibitor of eIF4A inhibits MYC expression and suppresses tumor growth in vivo. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25934076      PMCID: PMC5166973          DOI: 10.1158/2159-8290.CD-14-1040

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  44 in total

1.  Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.

Authors:  Christina M Rodrigo; Regina Cencic; Stéphane P Roche; Jerry Pelletier; John A Porco
Journal:  J Med Chem       Date:  2011-12-19       Impact factor: 7.446

Review 2.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

3.  Control of cell number by Drosophila FOXO: downstream and feedback regulation of the insulin receptor pathway.

Authors:  Oscar Puig; Michael T Marr; M Laure Ruhf; Robert Tjian
Journal:  Genes Dev       Date:  2003-07-31       Impact factor: 11.361

4.  Canonical initiation factor requirements of the Myc family of internal ribosome entry segments.

Authors:  Keith A Spriggs; Laura C Cobbold; Catherine L Jopling; Rebecca E Cooper; Lindsay A Wilson; Mark Stoneley; Mark J Coldwell; Didier Poncet; Ya-Ching Shen; Simon J Morley; Martin Bushell; Anne E Willis
Journal:  Mol Cell Biol       Date:  2009-01-05       Impact factor: 4.272

Review 5.  Molecular mechanisms of mTOR-mediated translational control.

Authors:  Xiaoju Max Ma; John Blenis
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04-02       Impact factor: 94.444

6.  Comprehensive molecular characterization of human colon and rectal cancer.

Authors: 
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962

7.  Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.

Authors:  Pixu Liu; Hailing Cheng; Stephanie Santiago; Maria Raeder; Fan Zhang; Adam Isabella; Janet Yang; Derek J Semaan; Changzhong Chen; Edward A Fox; Nathanael S Gray; John Monahan; Robert Schlegel; Rameen Beroukhim; Gordon B Mills; Jean J Zhao
Journal:  Nat Med       Date:  2011-08-07       Impact factor: 53.440

8.  Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.

Authors:  Aruna D Balgi; Bruno D Fonseca; Elizabeth Donohue; Trevor C F Tsang; Patrick Lajoie; Christopher G Proud; Ivan R Nabi; Michel Roberge
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

9.  Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency.

Authors:  Maria Barna; Aya Pusic; Ornella Zollo; Maria Costa; Nadya Kondrashov; Eduardo Rego; Pulivarthi H Rao; Davide Ruggero
Journal:  Nature       Date:  2008-11-16       Impact factor: 49.962

10.  The insulin receptor cellular IRES confers resistance to eIF4A inhibition.

Authors:  Calla M Olson; Marissa R Donovan; Michael J Spellberg; Michael T Marr
Journal:  Elife       Date:  2013-07-16       Impact factor: 8.140

View more
  47 in total

1.  PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Authors:  Kenji Zennami; Su Mi Choi; Ross Liao; Ying Li; Wikum Dinalankara; Luigi Marchionni; Fatema H Rafiqi; Akira Kurozumi; Koji Hatano; Shawn E Lupold
Journal:  Mol Cancer Res       Date:  2018-12-05       Impact factor: 5.852

2.  The MYC mRNA 3'-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels.

Authors:  Francesca R Dejure; Nadine Royla; Steffi Herold; Jacqueline Kalb; Susanne Walz; Carsten P Ade; Guido Mastrobuoni; Jens T Vanselow; Andreas Schlosser; Elmar Wolf; Stefan Kempa; Martin Eilers
Journal:  EMBO J       Date:  2017-04-13       Impact factor: 11.598

3.  FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation.

Authors:  Tuan M Nguyen; Elena B Kabotyanski; Yongchao Dou; Lucas C Reineke; Peng Zhang; Xiang H-F Zhang; Anna Malovannaya; Sung Yun Jung; Qianxing Mo; Kevin P Roarty; Yiwen Chen; Bing Zhang; Joel R Neilson; Richard E Lloyd; Charles M Perou; Matthew J Ellis; Jeffrey M Rosen
Journal:  Cancer Res       Date:  2018-05-29       Impact factor: 12.701

4.  Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.

Authors:  Long-Sheng Chang; Janet L Oblinger; Sarah S Burns; Jie Huang; Larry W Anderson; Melinda G Hollingshead; Rulong Shen; Li Pan; Garima Agarwal; Yulin Ren; Ryan D Roberts; Barry R O'Keefe; A Douglas Kinghorn; Jerry M Collins
Journal:  Mol Cancer Ther       Date:  2019-12-17       Impact factor: 6.261

Review 5.  Developing anti-neoplastic biotherapeutics against eIF4F.

Authors:  Jutta Steinberger; Jennifer Chu; Rayelle Itoua Maïga; Katia Sleiman; Jerry Pelletier
Journal:  Cell Mol Life Sci       Date:  2016-12-21       Impact factor: 9.261

6.  Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.

Authors:  Janet L Oblinger; Sarah S Burns; Elena M Akhmametyeva; Jie Huang; Li Pan; Yulin Ren; Rulong Shen; Beth Miles-Markley; Aaron C Moberly; A Douglas Kinghorn; D Bradley Welling; Long-Sheng Chang
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

Review 7.  New frontiers in translational control of the cancer genome.

Authors:  Morgan L Truitt; Davide Ruggero
Journal:  Nat Rev Cancer       Date:  2016-04-26       Impact factor: 60.716

8.  CIP2A regulates MYC translation (via its 5'UTR) in colorectal cancer.

Authors:  S Denk; S Schmidt; Y Schurr; G Schwarz; F Schote; M Diefenbacher; C Armendariz; F Dejure; M Eilers; Armin Wiegering
Journal:  Int J Colorectal Dis       Date:  2020-10-19       Impact factor: 2.571

Review 9.  Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy.

Authors:  Miljana Nenkov; Yunxia Ma; Nikolaus Gaßler; Yuan Chen
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

Review 10.  The long journey to bring a Myc inhibitor to the clinic.

Authors:  Jonathan R Whitfield; Laura Soucek
Journal:  J Cell Biol       Date:  2021-06-23       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.